Renal Denervation for Managing Hypertension

A scientific statement from the American Heart Association provides guidance on this recently U.S. FDA-approved procedure.

Sponsoring Organization: American Heart Association

Background

In 2009, NEJM Journal Watch covered one of the first published studies of renal denervation (RDN) as a potential treatment for hypertension (NEJM JW Cardiol May 2009 and Lancet 2009; 373:1275). Many clinicians might not realize that in late 2023, fully 15 years later, the U.S. FDA finally approved two RDN systems as “adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.” These catheter-based systems diminish renal sympathetic nerve activity through ultrasound (the Paradise system) or radiofrequency (the Symplicity system) ablation; the renal arteries are accessed via a femoral artery…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Renal Denervation for Managing Hypertension

Topics

Background

Reviewing Author